ARS Pharmaceuticals (SPRY) Enterprise Value (2020 - 2026)

ARS Pharmaceuticals has disclosed Enterprise Value across 7 years of filings, most recently posting -$201.0 million for Q1 2026.

• Enterprise Value for Q1 2026 came in at -$201.0 million, up 27.11% year-over-year; the trailing twelve-month figure through Mar 2026 was -$201.0 million (up 27.11% YoY), and the FY2025 annual result was -$245.0 million, up 21.98% from the prior year.
• Enterprise Value came in at -$201.0 million for Q1 2026 at ARS Pharmaceuticals, up from -$245.0 million in the prior quarter.
• In the past five years, Enterprise Value ranged from a high of -$201.0 million in Q1 2026 to a low of -$314.0 million in Q4 2024.
• The 5-year median for Enterprise Value is -$252.2 million (2023), against an average of -$250.1 million.
• Peak annual rise in Enterprise Value reached 32.16% in 2022, while the deepest fall reached 356.82% in 2022.
• ARS Pharmaceuticals' Enterprise Value stood at -$274.4 million in 2022, then climbed by 16.77% to -$228.4 million in 2023, then sank by 37.51% to -$314.0 million in 2024, then gained by 21.98% to -$245.0 million in 2025, then rose by 17.97% to -$201.0 million in 2026.
• The last three Enterprise Value figures came in at -$201.0 million (Q1 2026), -$245.0 million (Q4 2025), and -$288.2 million (Q3 2025), per Business Quant data.